Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Repligen Corp (NASDAQ:RGEN)

33.80
Delayed Data
As of 11:08am ET
 -0.58 / -1.69%
Today’s Change
18.23
Today|||52-Week Range
42.48
+70.71%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.1B

Company Description

Repligen Corp. is a life sciences company, which focuses on the development, production and commercialization of products used in the process of manufacturing biological drugs. The company also manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. The company has developed and markets a series of OPUS line of pre-packed """"plug-and-play"""" chromatography columns used for biologics purification and sells test kits to ensure final product quality. Repligen was founded by Alexander Rich in May 1981 and is headquartered in Waltham, MA.

Contact Information

Repligen Corp.
41 Seyon Street
Waltham Massachusetts 02453
P:(781) 250-0111
Investor Relations:
(781) 419-1881

Employees

Shareholders

Mutual fund holders60.41%
Other institutional34.19%
Individual stakeholders15.16%

Top Executives

Tony J. HuntChief Executive & Operating Officer
Jon K. SnodgresChief Financial Officer
James R. RuscheSenior Vice President-Research & Development
Howard BenjaminVice President-Business Development
Stephen TingleyVice President-Sales & Marketing